Titan Medical the medical device company focused on the design, development and commercialisation of a robotic surgical system for application in minimally invasive surgery, announces that Chad A. Zaring has joined the Company as its CCO, a position carved out specifically for him. Mr. Zaring has deep experience developing and executing commercial strategies and driving sales for leading surgical robotics companies and will be responsible for the launch of Titan’s single-port robotic surgery system following receipt of regulatory clearances.
Mr. Zaring joins Titan from Medtronic, where, since September 2017 he was vice president robotics, imaging and navigation. Prior to Medtronic, he was with Mazor Robotics from May 2015 through the initiation of a Global Distribution Agreement in September 2017 that led to its subsequent acquisition by Medtronic. As vice president, national accounts and later vice president, U.S. sales, he developed the capital sales teams, established new sales channels and consistently exceeded sales goals. Earlier in his career, from 2004 to April 2015 Mr. Zaring held positions of increasing responsibility at Intuitive Surgical, and was a member of the leadership team that executed early and mid-stage adoption of their robotic surgery system across multiple surgical disciplines.
“Chad is the ideal professional to lead the commercialization of our single-port robotic surgical system, and we are thrilled he has chosen to join Titan Medical,” said Mr. McNally. “The timing couldn’t be better. We are at an inflection point in our company’s development as we prepare for successful execution of preclinical and clinical studies that will permit us to file for regulatory clearances both in the U.S. and the EU by the end of the year. We look forward to having such a talented and broadly experienced individual as Chad execute our sales strategy and further strengthen our in-house robotic commercial launch expertise.”
“I am excited to be joining Titan Medical and to advance my passion of introducing disruptive and life-changing technology, working to commercialize an innovative single-port robotic surgical system,” said Mr. Zaring. “I believe that single-port robotic surgery will be the next frontier in several surgical disciplines. I am committed to delivering on Titan’s vision of single-port robotic surgery with the highest standards and with relentless focus on our customers who will help us drive technology adoption. Titan will make an important contribution to patient health while addressing surgeon desires and filling a significant gap in the market landscape. Titan has already set a thoughtful, early commercial plan by initially targeting benign gynecologic indications and subsequently adding more applications over time.”
Mr. Zaring began his career at Merrill Lynch in 1999 as a financial sales consultant. He later held sales positions at Merck and Co. and at Ethicon Endo-Surgery, a Johnson & Johnson company. He holds a BA degree in biology from Juanita College in Huntington, Penn.